JP2024545584A5 - - Google Patents

Info

Publication number
JP2024545584A5
JP2024545584A5 JP2024527672A JP2024527672A JP2024545584A5 JP 2024545584 A5 JP2024545584 A5 JP 2024545584A5 JP 2024527672 A JP2024527672 A JP 2024527672A JP 2024527672 A JP2024527672 A JP 2024527672A JP 2024545584 A5 JP2024545584 A5 JP 2024545584A5
Authority
JP
Japan
Prior art keywords
nanoparticles
approximately
mol
section
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024545584A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/049537 external-priority patent/WO2023086465A1/en
Publication of JP2024545584A publication Critical patent/JP2024545584A/ja
Publication of JP2024545584A5 publication Critical patent/JP2024545584A5/ja
Pending legal-status Critical Current

Links

JP2024527672A 2021-11-12 2022-11-10 ペイロード分子を気道上皮に送達するための組成物 Pending JP2024545584A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163278973P 2021-11-12 2021-11-12
US63/278,973 2021-11-12
PCT/US2022/049537 WO2023086465A1 (en) 2021-11-12 2022-11-10 Compositions for the delivery of payload molecules to airway epithelium

Publications (2)

Publication Number Publication Date
JP2024545584A JP2024545584A (ja) 2024-12-10
JP2024545584A5 true JP2024545584A5 (cg-RX-API-DMAC7.html) 2025-11-18

Family

ID=84602585

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527672A Pending JP2024545584A (ja) 2021-11-12 2022-11-10 ペイロード分子を気道上皮に送達するための組成物

Country Status (5)

Country Link
US (1) US20250049727A1 (cg-RX-API-DMAC7.html)
EP (1) EP4429644A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024545584A (cg-RX-API-DMAC7.html)
CN (1) CN118829423A (cg-RX-API-DMAC7.html)
WO (1) WO2023086465A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117243922A (zh) 2022-04-29 2023-12-19 北京剂泰医药科技有限公司 脂质纳米颗粒
CN119143620A (zh) 2023-06-16 2024-12-17 北京剂泰医药科技有限公司 一种快速代谢的脂质化合物
KR102618727B1 (ko) * 2023-06-28 2023-12-28 (주)바이오솔릭스 핵산 전달용 지질 나노입자
WO2025180480A1 (zh) * 2024-03-01 2025-09-04 北京剂泰医药科技有限公司 靶向肌肉的脂质纳米颗粒
WO2026003403A1 (en) 2024-06-28 2026-01-02 Certest Biotec, S.L. Ionizable lipids and lipid nanoparticles containing them for extrahepatic delivery

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681702A (en) 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
US20030073640A1 (en) 1997-07-23 2003-04-17 Ribozyme Pharmaceuticals, Inc. Novel compositions for the delivery of negatively charged molecules
CA2597724A1 (en) 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
WO2008103276A2 (en) 2007-02-16 2008-08-28 Merck & Co., Inc. Compositions and methods for potentiated activity of biologicaly active molecules
EP2217221B1 (en) * 2007-10-17 2018-06-27 Korea Advanced Institute of Science and Technology Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same
WO2010021865A1 (en) 2008-08-18 2010-02-25 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
WO2010080724A1 (en) 2009-01-12 2010-07-15 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
ES2613498T3 (es) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
US9181295B2 (en) 2009-08-20 2015-11-10 Sirna Therapeutics, Inc. Cationic lipids with various head groups for oligonucleotide delivery
US20120253032A1 (en) 2009-10-08 2012-10-04 Merck Sharp & Dohme Corporation Novel cationic lipids with short lipid chains for oligonucleotide delivery
SI2506857T1 (en) 2009-12-01 2018-08-31 Translate Bio, Inc. Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases
US20130017223A1 (en) * 2009-12-18 2013-01-17 The University Of British Columbia Methods and compositions for delivery of nucleic acids
US20130116419A1 (en) 2010-01-22 2013-05-09 Daniel Zewge Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
WO2011143230A1 (en) 2010-05-10 2011-11-17 Alnylam Pharmaceuticals Methods and compositions for delivery of active agents
US20130123338A1 (en) 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
WO2011149733A2 (en) 2010-05-24 2011-12-01 Merck Sharp & Dohme Corp. Novel amino alcohol cationic lipids for oligonucleotide delivery
DK2575767T3 (en) 2010-06-04 2017-03-13 Sirna Therapeutics Inc HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
ES2987915T3 (es) 2010-09-20 2024-11-18 Sirna Therapeutics Inc Nuevos lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos
EP2621480B1 (en) 2010-09-30 2018-08-15 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012054365A2 (en) 2010-10-21 2012-04-26 Merck Sharp & Dohme Corp. Novel low molecular weight cationic lipids for oligonucleotide delivery
DK2635265T3 (en) 2010-11-05 2018-07-16 Sirna Therapeutics Inc New low molecular weight cyclic amine-containing cationic lipids for oligonucleotide delivery
US9999673B2 (en) 2011-01-11 2018-06-19 Alnylam Pharmaceuticals, Inc. PEGylated lipids and their use for drug delivery
EP4074693A1 (en) 2011-06-08 2022-10-19 Translate Bio, Inc. Cleavable lipids
US9126966B2 (en) 2011-08-31 2015-09-08 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
DE21212055T1 (de) 2011-12-07 2022-08-04 Alnylam Pharmaceuticals, Inc. Biologisch abbaubare lipide zur freisetzung von wirkstoffen
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
WO2013103659A1 (en) 2012-01-04 2013-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus
WO2013116126A1 (en) 2012-02-01 2013-08-08 Merck Sharp & Dohme Corp. Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
US9352042B2 (en) 2012-02-24 2016-05-31 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
KR20140048404A (ko) * 2012-10-11 2014-04-24 포항공과대학교 산학협력단 저밀도 지단백질 유사 나노입자 및 이를 포함하는 간 표적 진단 및 치료용 조성물
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
WO2014164253A1 (en) 2013-03-09 2014-10-09 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
CN105143456A (zh) 2013-03-15 2015-12-09 不列颠哥伦比亚大学 用于转染的脂质纳米粒子和相关方法
CA2953341C (en) 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
CN108368028B (zh) 2015-10-28 2021-09-03 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
JP7332478B2 (ja) * 2017-03-15 2023-08-23 モデルナティエックス インコーポレイテッド 脂質ナノ粒子製剤
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
EP3982932A4 (en) * 2019-06-14 2023-10-25 Particella, Inc. COMPOSITIONS AND METHODS FOR BIOLOGICAL RELEASE VEHICLES
WO2022032154A2 (en) * 2020-08-06 2022-02-10 Modernatx, Inc. Compositions for the delivery of payload molecules to airway epithelium
WO2023009422A1 (en) * 2021-07-26 2023-02-02 Modernatx, Inc. Processes for preparing lipid nanoparticle compositions for the delivery of payload molecules to airway epithelium

Similar Documents

Publication Publication Date Title
JP2023538260A5 (cg-RX-API-DMAC7.html)
JP2024527940A5 (cg-RX-API-DMAC7.html)
CN118319880B (zh) 靶向肺部高效递送核酸的脂质纳米颗粒、吸入式制剂及应用
US20250051263A1 (en) Novel ionizable lipids and lipid nanoparticles and methods of using the same
EP2567693B1 (en) Lipid encapsulated interfering RNA
TWI858802B (zh) 使用陽離子膽固醇用於核酸遞送的局部遞送的脂質納米顆粒
KR101476167B1 (ko) 약물 송달 제어용 경폐 투여 리포좀
US9233971B2 (en) Lipomacrocycles and uses thereof
CN107260679B (zh) 用以减少眼用类固醇的并发症的药物组合物
JP2023518944A5 (cg-RX-API-DMAC7.html)
EP4559894A1 (en) Amino lipid compound, preparation method therefor, and use thereof
WO2024019770A1 (en) Methods of making ionizable lipids and lipid nanoparticles for mrna delivery
US12582610B2 (en) Lipid-polymer compositions and methods of use
JP2024545584A (ja) ペイロード分子を気道上皮に送達するための組成物
JP7832717B2 (ja) 硫化物を含むイオン化可能な脂質、及びこれを含む脂質ナノ粒子
WO2024094194A1 (zh) 一种用于雾化吸入脂质纳米粒的通用型处方
EP4628496A1 (en) Steroid-cationic lipid compound and use thereof
TW202434543A (zh) 脂質化合物和脂質奈米顆粒組合物
US20260060926A1 (en) Novel ionizable lipids and lipid nanoparticles and methods of using the same
WO2024096516A1 (ko) 핵산 약물의 경폐전달을 위한 지질나노입자 제형 및 이의 활용
US12414918B2 (en) Pharmaceutical composition of lipid nanoparticle for delivering nucleic acid drug containing trehalose derivative and novel structure-maintaining lipid compound
TW202530174A (zh) 用於遞送的脂質化合物及脂質奈米顆粒
EP4626858A1 (en) Novel ionizable lipids and lipid nanoparticles comprising the same
US20230312620A1 (en) Phospholipid
NZ820531A (en) Long-acting spleen-targeting cationic lipid compound comprising benzene ring structure, composition comprising same, and use thereof